FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Market Closed - Börse Stuttgart 12:14:27 25/06/2024 BST | ||
| 134.3 EUR | +6.58% |
|
| Current month | +38.34% | ||
| 1 month | +30.87% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 25/06/24 | 134.3 | +6.58% |
| 24/06/24 | 126 | -0.91% |
| 21/06/24 | 127.2 | +1.83% |
| 20/06/24 | 124.9 | +2.92% |
| 19/06/24 | 121.3 | +1.00% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 12:14 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MA9Q98 |
| ISIN | DE000MA9Q986 |
| Date issued | 28/10/2021 |
| Strike | 741.4 kr |
| Maturity | Unlimited |
| Parity | 0.26 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 134.3 € |
|---|---|
| Lowest since issue | 4.62 € |
| Spread | 0.3 € |
| Spread % | 0.21% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,028
DKK
Average target price
938.1
DKK
Spread / Average Target
-8.74%
- Stock Market
- Certificates
- Certificat
